Kiora Pharmaceuticals
KPRX
14 hedge funds and large institutions have $284K invested in Kiora Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
27% more funds holding
Funds holding: 11 → 14 (+3)
4.06% less ownership
Funds ownership: 8.4% → 4.34% (-4.1%)
40% less capital inflows, than outflows
Capital inflows: $285K | Capital outflows: $474K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$89.1K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$58.7K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$43.6K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$41.5K |
| 5 |
NewEdge Advisors
New Orleans,
Louisiana
|
+$822 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Walleye Capital
New York
|
-$286K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$113K |
| 3 |
Boothbay Fund Management
New York
|
-$40.1K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$17.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$17K |
KPRX Hedge Fund Activity: Q1 2023 in Review
14 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q1 2023, worth a combined $284K — down 45% from $519K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new KPRX positions and 3 closed out — a net gain of 3 holders — while 0 added to existing stakes and 3 trimmed.
The largest buyer was Acadian Asset Management, opening a new position worth an estimated $89.1K. The largest seller was Walleye Capital, exiting entirely with an estimated $286K sold.
- 14 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q1 2023, up from 11 in Q4 2022.
- Funds reported $284K of Kiora Pharmaceuticals stock for Q1 2023, down 45% quarter-over-quarter.
- 6 funds opened new Kiora Pharmaceuticals positions in Q1 2023 and 3 closed out, a net change of +3 holders.
- The largest Kiora Pharmaceuticals buyer in Q1 2023 was Acadian Asset Management, an estimated $89.1K added.
- The largest Kiora Pharmaceuticals seller in Q1 2023 was Walleye Capital, an estimated $286K sold.
Based on aggregated 13F filings for Q1 2023.